Eastwood Bio-Medical Canada Inc

As of April 30, 2026, Eastwood Bio-Medical Canada Inc carries a market capitalization of 51.66M, placing it among publicly traded companies globally. Its enterprise value stands at 51.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Eastwood Bio-Medical Canada Inc has 68.89M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 69.90, and the price-to-book ratio stands at -30.10.

These figures are as of April 30, 2026. The EV/Sales ratio of 69.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 51.72M versus a market cap of 51.66M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, Eastwood Bio-Medical Canada Inc maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -136.74, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Eastwood Bio-Medical Canada Inc's stock has gained approximately 249.09% over the past 52 weeks. The 50-day moving average sits at 1.84, while the 200-day moving average is 1.08.

Over the twelve months ended April 30, 2026, Eastwood Bio-Medical Canada Inc generated 739,106.00 in revenue and converted that into -320,873.00 in net income, yielding earnings per share of 0.00. EBITDA reached -276,025.00, while operating income came in at -296,932.00.

As of April 30, 2026, Eastwood Bio-Medical Canada Inc holds 9,038.00 in cash and equivalents against 67,982.00 in total debt, resulting in a net debt position of 58,944.00. Total book value stands at -1.72M, with working capital of -1.88M providing operational flexibility.

Eastwood Bio-Medical Canada Inc produced 4,677.00 in operating cash flow over the twelve months ended April 30, 2026.

Over the twelve months ended April 30, 2026, Eastwood Bio-Medical Canada Inc posted a gross margin of 71.04, reflecting its pricing power and cost economics. The operating margin of -40.17 and net profit margin of -43.41 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield stands at 0.01, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.01, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Eastwood Bio-Medical Canada Inc shareholders.

As of April 30, 2026, Eastwood Bio-Medical Canada Inc has an Altman Z-Score of -27.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.